Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study.

Autor: Ozonoff A; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA., Jayavelu ND; Benaroya Research Institute, Seattle, WA, USA., Liu S; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA., Melamed E; The University of Texas at Austin, Austin, TX, USA., Milliren CE; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA., Qi J; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Geng LN; Stanford University, Stanford, CA, USA., McComsey GA; Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA., Cairns CB; Drexel University/Tower Health Hospital, Philadelphia, PA, USA., Baden LR; Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Schaenman J; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA., Shaw AC; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA., Samaha H; Emory University, Atlanta, GA, USA., Seyfert-Margolis V; MyOwnMed, Inc, Bethesda, MD, USA., Krammer F; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rosen LB; National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA., Steen H; Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Syphurs C; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA., Dandekar R; University of California San Francisco School of Medicine, San Francisco, CA, USA., Shannon CP; Centre for Heart Lung Innovation, Providence Research, St. Paul's Hospital, and the PROOF Centre of Excellence, Vancouver, BC, Canada., Sekaly RP; Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA., Ehrlich LIR; The University of Texas at Austin, Austin, TX, USA., Corry DB; Baylor College of Medicine, and the Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, USA., Kheradmand F; Baylor College of Medicine, and the Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, USA., Atkinson MA; University of Florida/University of South Florida, Tampa, FL, USA., Brakenridge SC; University of Florida/University of South Florida, Tampa, FL, USA., Higuita NIA; Oklahoma University Health Sciences Center, Oklahoma City, OK, USA., Metcalf JP; Oklahoma University Health Sciences Center, Oklahoma City, OK, USA., Hough CL; Oregon Health & Science University, Portland, OR, USA., Messer WB; Oregon Health & Science University, Portland, OR, USA., Pulendran B; Stanford University, Stanford, CA, USA., Nadeau KC; Stanford University, Stanford, CA, USA., Davis MM; Stanford University, Stanford, CA, USA., Sesma AF; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Simon V; Icahn School of Medicine at Mount Sinai, New York, NY, USA., van Bakel H; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kim-Schulze S; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Hafler DA; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA., Levy O; Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Kraft M; University of Arizona, Tucson, AZ, USA., Bime C; University of Arizona, Tucson, AZ, USA., Haddad EK; Drexel University/Tower Health Hospital, Philadelphia, PA, USA., Calfee CS; University of California San Francisco School of Medicine, San Francisco, CA, USA., Erle DJ; University of California San Francisco School of Medicine, San Francisco, CA, USA., Langelier CR; University of California San Francisco School of Medicine, San Francisco, CA, USA., Eckalbar W; University of California San Francisco School of Medicine, San Francisco, CA, USA., Bosinger SE; Emory University, Atlanta, GA, USA., Peters B; La Jolla Institute for Immunology, La Jolla, CA, USA., Kleinstein SH; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA., Reed EF; David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA., Augustine AD; National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA., Diray-Arce J; Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA., Maecker HT; Stanford University, Stanford, CA, USA., Altman MC; Benaroya Research Institute, Seattle, WA, USA., Montgomery RR; Yale School of Medicine, and Yale School of Public Health, New Haven, CT, USA., Becker PM; National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA., Rouphael N; Emory University, Atlanta, GA, USA. nroupha@emory.edu.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Jan 03; Vol. 15 (1), pp. 216. Date of Electronic Publication: 2024 Jan 03.
DOI: 10.1038/s41467-023-44090-5
Abstrakt: Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: